Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GH Research PLC filings document foreign private issuer current reports for a clinical-stage biopharmaceutical company developing mebufotenin product candidates for depression. The company’s Form 6-K reports furnish press releases, corporate presentations, manuscripts, and conference materials related to GH001 in treatment-resistant depression, including Phase 2b results, open-label extension data, and FDA/IND regulatory updates.
The filing record also covers operating and financial results, material-event disclosures, shareholder voting matters, capital-structure information, material agreements, and clinical or regulatory disclosures. These documents describe the company’s research and development focus, product-candidate pipeline, governance reporting, and formal exhibits used to communicate trial publications and business updates.
GH Research plc reports new clinical data on its inhaled psychedelic candidate GH001 in treatment-resistant depression. In a randomized Phase 2b trial with a 6‑month open-label extension, 81 patients were treated with either GH001 or placebo and then all received GH001 in the extension. Suicidal ideation and behavior were assessed repeatedly using the Columbia-Suicide Severity Rating Scale and MADRS item 10.
No treatment-emergent adverse events of suicidal intent or suicidal behavior occurred over 6 months. One patient had a treatment-emergent adverse event of suicidal ideation lasting 6 hours and resolving spontaneously. Baseline suicidality and changes through Day 8 were generally similar between GH001 and placebo, and the proportion of patients with zero suicidality scores increased over time during the extension. The company concludes that GH001 was generally well tolerated and associated with significant reductions in depressive symptoms without increasing suicide risk in this TRD population.
GH Research PLC reports that it has been accepted to the Promising Targets Oral Session at the 64th American College of Neuropsychopharmacology annual meeting. The company will present results from its GH001-TRD-201 clinical trial, which focuses on treatment‑resistant depression, during this scientific congress. The meeting is scheduled for January 12–15, 2026 in Nassau, Bahamas, and the presentation will be delivered by Prof Michael E. Thase. An abstract of the presentation content is provided as an exhibit to this report, giving additional detail on the trial results to the scientific and investment community.
GH Research PLC (GHRS) reported that it will participate in a fireside chat and hold one-on-one investor meetings during the Stifel 2025 Healthcare Conference in New York. The conference is scheduled for November 11–13, 2025.
This is a routine investor-relations update that signals engagement with the investment community through a formal conference appearance and direct meetings.
GH Research PLC furnished a Form 6-K announcing third quarter 2025 financial results, business updates, and an updated investor presentation. The company made available a press release and presentation dated November 6, 2025.
The submission includes unaudited interim financial statements and MD&A, plus Inline XBRL files. The report (excluding Exhibits 99.3 and 99.4) is incorporated by reference into the company’s Form S-8 registrations and its Form F-3 shelf.
GH Research PLC reported that posters from its GH001-TRD-201 clinical program were accepted for presentation at the 64th American College of Neuropsychopharmacology annual meeting, scheduled for January 12–15, 2026 in Nassau, Bahamas. The submission set includes three abstracts: suicidal ideation and behavior in treatment-resistant depression (Ex. 99.1; presenter Sanjay J. Mathew), rapid antidepressant effects of inhaled GH001 in treatment-resistant depression from a Phase 2b randomized trial with 6‑month follow-up (Ex. 99.2; presenter Lisa Harding), and efficacy and safety of inhaled mebufotenin (GH001) in Bipolar II depression from a Phase 2a trial (Ex. 99.3; presenter Andreas Reif).
GH Research PLC filed a Form 6-K announcing the presentation of data from its GH001-TRD-201 clinical trial at the 38th European College of Neuropsychopharmacology annual meeting in Amsterdam. The Congress is scheduled for October 11–14, 2025.
The presentation, delivered by Prof. Wiesław J. Cubała on October 13, 2025 during the Novel Therapies Symposium, is provided as Exhibit 99.1. This update is informational and centers on the public disclosure of clinical data via a scientific conference presentation.
GH Research PLC reports that it will present clinical data from its GH001-TRD-201 trial in treatment-resistant depression at the 38th European College of Neuropsychopharmacology (ECNP) annual meeting in Amsterdam from October 11-14, 2025.
One poster, presented by Dr. Fabian Devlin on October 13, 2025, will cover the psychoactive effects of GH001 in patients with treatment-resistant depression from a Phase 2b, double-blind, randomised controlled trial. A second poster, presented by Prof. Bernhard T. Baune on October 14, 2025, will address safety and tolerability results from the same Phase 2b, double-blind trial with an open-label extension of GH001 in treatment-resistant depression.
GH Research PLC filed a report stating that it will participate in the 38th European College of Neuropsychopharmacology annual meeting, scheduled for October 11-14, 2025 in Amsterdam, the Netherlands. The company highlights this scientific and medical conference appearance through an attached press release, which is included as an exhibit.
The report notes that the press release is provided as of October 9, 2025 and clarifies that its availability should not be seen as an admission that the information is material. GH Research also states it does not undertake any obligation to update that press release or its forward-looking statements after that date.
GH Research PLC has filed an update stating that it will present data from its GH001-BD-202 clinical trial at the International Society for Bipolar Disorders Annual Meeting in Chiba, Japan, scheduled for September 17-19, 2025. The study evaluates inhaled mebufotenin (GH001) in patients with bipolar II disorder who are experiencing a current major depressive episode. A scientific poster titled “Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode”, to be presented by PD Dr. med. Philipp Ritter during Poster Session II, is attached as an exhibit. This filing mainly informs investors that detailed clinical data will be shared in a scientific forum and made available in the attached poster.
GH Research PLC filed an update stating it will participate in the Cantor Global Healthcare Conference in New York. The event is scheduled to take place from September 3-5, 2025, and the company plans to join a fireside chat and hold one-on-one meetings with investors. This type of participation is typically used to share the company’s story, engage with the investment community, and address investor questions in a conference setting.